Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | XDH | P47989 | 4/20 | 1.00 |
| ▸ | MAOA | P21397 | 3/20 | 1.00 |
| ▸ | EPHX2 | P34913 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | HES1 | Q14469 | 2/20 | 1.00 |
| ▸ | FANCF | Q9NPI8 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | KDM1A | O60341 | 1/20 | 1.00 |
| ▸ | PRSS1 | P07477 | 1/20 | 1.00 |
| ▸ | PRSS2 | P07478 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | HMGB1 | P09429 | 1/20 | 1.00 |
| ▸ | CFTR | P13569 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | PRSS3 | P35030 | 1/20 | 1.00 |
| ▸ | BACE1 | P56817 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rutin SCHEMBL15263233 | 1.00 | KDM4E (1.00) | KDM4EXDHMAOAEPHX2MAPT | |
| Rutin SCHEMBL13696608 | 1.00 | KDM4E (1.00) | KDM4EXDHMAOAEPHX2MAPT | |
| Rutin SCHEMBL20576343 | 1.00 | KDM4E (1.00) | KDM4EXDHMAOAEPHX2MAPT | |
| Rutin SCHEMBL13696392 | 1.00 | KDM4E (1.00) | KDM4EXDHMAOAEPHX2MAPT | |
| Rutin SCHEMBL21424757 | 1.00 | KDM4E (1.00) | KDM4EXDHMAOAEPHX2MAPT | |
| Rutin SCHEMBL23663918 | 1.00 | KDM4E (1.00) | KDM4EXDHMAOAEPHX2MAPT | |
| Rutin SCHEMBL21013017 | 1.00 | KDM4E (1.00) | KDM4EXDHMAOAEPHX2MAPT | |
| Rutin SCHEMBL21325433 | 1.00 | KDM4E (1.00) | KDM4EXDHMAOAEPHX2MAPT | |
| Rutin SCHEMBL21699244 | 1.00 | KDM4E (1.00) | KDM4EXDHMAOAEPHX2MAPT | |
| Rutin SCHEMBL15025698 | 1.00 | KDM4E (1.00) | KDM4EXDHMAOAEPHX2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11872241-B2 | Compositions and methods for reducing major thrombotic events in cancer patients | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230346833-A1 | POROUS SILICATE AND/OR ALUMINOSILICATE MATRIX/CERIUM OXIDE NANOPARITLE NANOCARRIER FOR COMBINATION ANTI-CANCER THERAPEUTIC AND ANTIOXIDANT DELIVERY | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2023-11-02 | — | — | US | disclosed |
| US-11779652-B2 | Porous silicate/magnetic ferrite nanocarrier for combination anti-cancer therapeutic and antioxidant delivery | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2023-10-10 | — | — | US | disclosed |
| US-20220401572-A1 | POROUS SILICATE/MAGNETIC FERRITE NANOCARRIER FOR COMBINATION ANTI-CANCER THERAPEUTIC AND ANTIOXIDANT DELIVERY | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2022-12-22 | — | — | US | disclosed |
| US-20210220323-A1 | COMPOSITIONS COMPRISING COMBINATIONS OF PURIFIED CANNABINOIDS, WITH AT LEAST ONE FLAVONOID, TERPENE OR MINERAL | ebbu, Inc. | 2021-07-22 | — | — | US | disclosed |
| US-20200385762-A1 | Means and Methods for the Production of Terpenoids | UNIVERSITEIT GENT (BE) | 2020-12-10 | — | — | US | disclosed |
| US-20200171064-A1 | COMPOSITIONS AND METHODS FOR REDUCING MAJOR THROMBOTIC EVENTS IN CANCER PATIENTS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2020-06-04 | — | — | US | disclosed |
| US-10233206-B2 | D-fagomine for the control of inflammatory processes related to an overactivation of the humoral immune response | SERGIO PUMAROLA SEGURA (ES) | 2019-03-19 | — | — | US | disclosed |
| US-20170266153-A1 | COMPOSITIONS PURPOSEFULLY SELECTED COMPRISING PURIFIED CANNABINOIDS AND/OR PURIFIED TERPENES | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2017-09-21 | — | — | US | disclosed |
| US-9713624-B1 | Synthesis of rutin nanotubes | KING SAUD UNIVERSITY (SA) | 2017-07-25 | — | — | US | disclosed |
| US-20120071428-A1 | NANOCRYSTALLINE PHOTOCATALYTIC COLLOID, A METHOD OF PRODUCING IT AND ITS USE | JAGIELLONIAN UNIVERSITY (PL) | 2012-03-22 | — | — | US | disclosed |
| US-20080139664-A1 | ANTI-GLYCATION AGENTS FOR PREVENTING AGE-, DIABETES-, AND SMOKING-RELATED COMPLICATIONS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200171064-A1 | COMPOSITIONS AND METHODS FOR REDUCING MAJOR THROMBOTIC EVENTS IN CANCER PATIENTS | SELP, SELE, SELPLG | KDM4E 3842/4885XDH 965/4885MAOA 2498/4885 |
| US-20080139664-A1 | ANTI-GLYCATION AGENTS FOR PREVENTING AGE-, DIABETES-, AND SMOKING-RELATED COMPLICATIONS | AGER, GID4, GALE | KDM4E 1615/4885XDH 1066/4885MAOA 197/4885 |
| US-11872241-B2 | Compositions and methods for reducing major thrombotic events in cancer patients | SELP, SELE, SELPLG | KDM4E 3842/4885XDH 965/4885MAOA 2498/4885 |
| US-20120071428-A1 | NANOCRYSTALLINE PHOTOCATALYTIC COLLOID, A METHOD OF PRODUCING IT AND ITS USE | UROD, CRYZ, CRYAB | KDM4E 1774/4885XDH 4649/4885MAOA 1830/4885 |
| US-11779652-B2 | Porous silicate/magnetic ferrite nanocarrier for combination anti-cancer therapeutic and antioxidant delivery | SLC40A1, AIFM2, FECH | KDM4E 2341/4885XDH 1530/4885MAOA 782/4885 |
| US-20220401572-A1 | POROUS SILICATE/MAGNETIC FERRITE NANOCARRIER FOR COMBINATION ANTI-CANCER THERAPEUTIC AND ANTIOXIDANT DELIVERY | SLC40A1, AIFM2, FECH | KDM4E 2341/4885XDH 1530/4885MAOA 782/4885 |
| US-20210220323-A1 | COMPOSITIONS COMPRISING COMBINATIONS OF PURIFIED CANNABINOIDS, WITH AT LEAST ONE FLAVONOID, TERPENE OR MINERAL | CNR2, CNR1, MAG | KDM4E 577/4885XDH 3859/4885MAOA 840/4885 |
| US-10233206-B2 | D-fagomine for the control of inflammatory processes related to an overactivation of the humoral immune response | TLR5, CD74, FCGR1A | KDM4E 4876/4885XDH 1788/4885MAOA 195/4885 |
| US-20230346833-A1 | POROUS SILICATE AND/OR ALUMINOSILICATE MATRIX/CERIUM OXIDE NANOPARITLE NANOCARRIER FOR COMBINATION ANTI-CANCER THERAPEUTIC AND ANTIOXIDANT DELIVERY | CAT, SP1, GPX1 | KDM4E 2947/4885XDH 1117/4885MAOA 1476/4885 |
| US-20170266153-A1 | COMPOSITIONS PURPOSEFULLY SELECTED COMPRISING PURIFIED CANNABINOIDS AND/OR PURIFIED TERPENES | CNR2, CNR1, FAAH | KDM4E 943/4885XDH 4711/4885MAOA 3650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.